Meeting
2014 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (Pts) with metastatic solid tumors.
Authors
Rahul Raj Aggarwal
University of California, San Francisco, San Francisco, CA
Rahul Raj Aggarwal , Jennifer A. Grabowsky , Anne Reinert , Scott Thomas , Paromita Raha , Thierry Marie Jahan , Alain Patrick Algazi , Terence W. Friedlander , Thach-Giao Truong , Saloni Mathur , Pamela N. Munster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Epigenetics
Clinical Trial Registration Number
NCT01543763
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2577)
DOI
10.1200/jco.2014.32.15_suppl.2577
Abstract #
2577
Poster Bd #
40
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I study of pazopanib (PAZ) in combination with abexinostat (ABX) in patients (pts) with metastatic solid tumors.
First Author: Rahul Raj Aggarwal
Poster
2013 ASCO Annual Meeting
Phase I study of pazopanib (PAZ) in combination with PCI-24781 (PCI) in patients (pts) with metastatic solid tumors with new tumor proliferation imaging correlates in renal cell carcinoma (RCC) and sarcoma.
First Author: Thach-Giao Truong
Poster
2016 ASCO Annual Meeting
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: A phase 1 study in advanced solid tumor malignancies.
First Author: Rahul Raj Aggarwal
Poster
2018 ASCO Annual Meeting
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).
First Author: Andrew J. Wagner